Related Experiment Video
Updated: Jun 20, 2026
08:22
Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Targeting Neuroinflammation in Adult Ischemic Stroke: Direct Immunotherapy, Regenerative Cell-Based Strategies, and
Júlia Cera1,2, Wirginia Krzyściak3
1Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.
Molecular Neurobiology
|June 18, 2026
Summary
Current immunotherapies show promise for adult ischemic stroke by modulating neuroinflammation, but clinical benefits remain inconsistent. Further research is needed to optimize these strategies for effective stroke treatment.
Area of Science:
- Neuroscience
- Immunology
- Neurology
Background:
- Neuroinflammation and immune processes significantly impact adult ischemic stroke pathology, affecting acute injury, secondary damage, and later recovery phases.
- Immunotherapeutic interventions show potential for modulating inflammatory cascades and immune cell activation, aiming for neuroprotection and neurorestoration.
Purpose of the Study:
- To systematically review preclinical and clinical evidence on neuroinflammation-targeted immunotherapies in adult ischemic stroke.
- To differentiate direct immunotherapy from regenerative cell-based approaches with immunomodulatory effects.
Main Methods:
- Systematic search of PubMed/MEDLINE and Embase (Jan 2020-Dec 2025) for eligible preclinical and clinical studies.
- Qualitative synthesis of 55 studies; exploratory meta-analysis of 3 RCTs on functional outcome at day 90.
- Categorization of therapies into molecular immunotherapy, biological immunotherapy, and regenerative cell-based therapies.
Main Results:
- Molecular interventions reduced neuroinflammation in preclinical models, but human evidence is limited.
- Regenerative cell therapies showed favorable safety and immunomodulatory effects, but modest and inconsistent clinical benefits.
- Biological immunotherapies had acceptable safety but lacked consistent functional benefits in RCTs; meta-analysis showed no significant pooled benefit.
Conclusions:
- Neuroinflammation-targeted immunotherapies and regenerative cell strategies are biologically plausible with acceptable safety profiles in early studies.
- Current evidence is insufficient to support consistent clinical benefit due to heterogeneity and potentially underpowered trials.
- Future research requires mechanism-driven trials, standardized outcomes, patient stratification, and optimized therapeutic windows for immune-targeted stroke interventions.
